Healthy Clinical Trial
Official title:
Influence of Repetitive Transcranial Magnetic Stimulation (rTMS) Challenge on Cognitive and Functional Magnetic Resonance Imaging Markers in Healthy Subjects
Verified date | May 2013 |
Source | Qualissima |
Contact | n/a |
Is FDA regulated | No |
Health authority | Spain: Comité Ético de Investigación Clínica |
Study type | Interventional |
Episodic and working memory processes are the most affected cognitive domains in Alzheimer's
Disease (AD) and its early stage, Mild Cognitive Impairment (MCI). Transcranial Magnetic
Stimulation (TMS) is a unique tool to interfere with cognitive processes by inducing
"virtual and transient lesions", mimicking those observed in MCI. It has proven repeatedly
its capacity to interfere with encoding-retrieval memory task. However, to date, only few
imaging data exist on the cerebral pathways involved in encoding memory task. Moreover, the
stability of TMS effects over time remains to be investigated. If proven to be a stable
interfering challenge, TMS could be used to investigate the potential restoring effect of
new medication in AD.
The study is the pilot study of a larger clinical trial which aims to prove the utility of
rTMS as a potential model for prediction of clinical efficacy using a combination of
cognitive and neuroimaging endpoints.
Status | Terminated |
Enrollment | 14 |
Est. completion date | December 2012 |
Est. primary completion date | December 2012 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 40 Years |
Eligibility |
Inclusion Criteria: Demography 1. Healthy male subjects aged between 18 and 40 years-old inclusive. 2. BMI between 18 kg/m2 to 29 kg/m2. 3. Education level: at least secondary. 4. Right-handed (Edinburgh Handedness Inventory). - Health status 5. The subjects is in good health on the basis of the medical interview (medical history, symptoms) and the physical examination, vital signs. 6. No history of psychiatric or neurological disorders as assessed by Structured Clinical Interview for DSM IV Disorders (SCID). 7. No history of concussion with loss of consciousness more than 20 min. 8. No history of drug or alcohol abuse. - Specific to the study 9. The subject can complete the neuropsychological test battery during the training session. - Regulations 10. The subject is able to read and understand the Information Form and comply with the protocol instructions and restrictions 11. The subject is covered by a social insurance 12. The subject have provided written informed consent Exclusion Criteria: - Medical history and clinical status 1. History or presence of psychiatric illness (Psychiatric interview). 2. History or presence of neurologic illness. - General conditions 3. The subject, in the opinion of the investigator, is unlikely to comply with the study protocol or is unsuitable for any other reason. 4. The subject participates in another clinical trial or is still being within a washout period of 1 month since last taking of a previous clinical trial, or subjects who have received more than 4500 Euros in the previous 12 months for participating in clinical trials. - Specific to the study 5. Presence of metallic objects within the head. 6. Subjects with pacemaker. 7. Claustrophobia. 8. Individual and familial history of seizure. 9. Any medication listed in the safety guidelines published by the Safety of TMS Consensus Group (Rossi et al., 2009) will be forbidden. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science
Country | Name | City | State |
---|---|---|---|
Spain | IDIBAPS | Barcelona |
Lead Sponsor | Collaborator |
---|---|
Qualissima | Pharmacog's project (IMI) |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Part A: Location of cerebral activities | Primary endpoints: The location of cerebral activities elicited by the retrieval session of the episodic memory task during fMRI will be the primary endpoint of PART A. PART A will assess task-elicited BOLD signal modifications and determine the target location coordinates and verify the stability of the BOLD signal responses over time and the stability of the target location |
Day 1 | No |
Primary | Part B: Outputs of the memory task | Outputs: the number of correct answers during the retrieval blocks (Hit rates)and the number of false recognition of novel pictures (False Alarms rate). | Change between Day 2 and Day 1 | No |
Secondary | Part A: The outputs of the memory task | Memory task. The output of the task will be the number of correct answers during the retrieval blocks (i.e. correctly recognized images presented during the encoding blocks, Hits rate) and the number of false recognition of novel pictures (False Alarms rate). | Day 1 and Day 2 | No |
Secondary | Part B: Imaging and CANTAB tasks | Imaging (functional MRI): Modifications will be highlighted by changes in the Blood-Oxygen-Level Dependence (BOLD) signal patterns. CANTAB tasks: CANTAB / Rapid Visual Information Processing (RVP) with outcome measures: latency, probabilities and sensitivity and hits, misses, false alarms and rejections; CANTAB / Spatial Working Memory (SWM) with outcome measures: errors, strategy and latency measures. CANTAB / Paired Associates Learning (PAL) with outcome measures: errors, number of trials required to locate the pattern(s) correctly, memory scores. |
Day 1, 2, 3 and 4 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |